1. Ability to provide written informed consent (by the parents or legally acceptable/authorized representative (LAR) and assent by the children aged between �7 to <18 years. <br/ >2. Subject, in the opinion of the investigator, has ability to communicate and willingness to comply with the requirements of the protocol. <br/ >3. Participants of either gender of age between <18years to �5 (Participant should be <18 years at the time of Screening of the study). <br/ >4. Participants virologically seronegative to SARS-CoV-2 infection by RT-PCR and anti-SARS-CoV-2 antibody prior to enrolment. <br/ >5. Participants considered of stable health as judged by the investigator, determined by medical history and physical examination with normal vital signs as defined in the protocol. [Normal vital sign defined as body temperature <100.4ºF prior to enrolment]. <br/ >6. Agrees not to participate in another clinical trial at any time during the total study period. <br/ >7. Agrees to remain in the town where the study centre is located, for the entire duration of the study. <br/ >8. Willing to allow storage and future use of collected biological samples for future research in an anonymised form. <br/ >

1. Ability to provide written informed consent (by the parents or legally acceptable/authorized representative (LAR) and assent by the children aged between �7 to <18 years. <br/ >2. Subject, in the opinion of the investigator, has ability to communicate and willingness to comply with the requirements of the protocol. <br/ >3. Participants of either gender of age between <18years to �5 (Participant should be <18 years at the time of Screening of the study). <br/ >4. Participants virologically seronegative to SARS-CoV-2 infection by RT-PCR and anti-SARS-CoV-2 antibody prior to enrolment. <br/ >5. Participants considered of stable health as judged by the investigator, determined by medical history and physical examination with normal vital signs as defined in the protocol. [Normal vital sign defined as body temperature <100.4ºF prior to enrolment]. <br/ >6. Agrees not to participate in another clinical trial at any time during the total study period. <br/ >7. Agrees to remain in the town where the study centre is located, for the entire duration of the study. <br/ >8. Willing to allow storage and future use of collected biological samples for future research in an anonymised form. <br/ >